ORIGINAL PAPER
Fosfomycin prophylaxis can reduce the risk of severe recurrent urinary tract infections requiring hospitalisation in children with complex urinary tract malformations
 
More details
Hide details
1
Department of Paediatrics, Immunology and Nephrology, Polish Mother’s Memorial Hospital Research Institute of Lodz, Lodz, Poland
 
2
Department of Paediatrics, Nephrology and Immunology, Medical University of Lodz, Lodz, Poland
 
3
Centre for Medical Laboratory Diagnostics and Screening, Laboratory of Microbiology and Parasitology, Polish Mother’s Memorial Hospital Research Institute of Lodz, Lodz, Poland
 
 
Submission date: 2022-12-19
 
 
Final revision date: 2023-07-11
 
 
Acceptance date: 2023-07-18
 
 
Publication date: 2023-12-15
 
 
Pediatr Pol 2023;98(4):285-292
 
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Urinary tract infections (UTIs) with resistant bacterial strains are one of the most troublesome problems in children with severe congenital anomalies of the kidney and urinary tract (CAKUT). We present the results of non-standard prophylactic treatment with fosfomycin of infants with complex urinary tract malformations.

Material and methods:
It was a retrospective analysis of data of 5 male infants after urological interventions due to complex CAKUT. The frequency of UTIs, their aetiology and course, frequency and duration of hospitalisation due to UTIs, prophylaxis and treatment outcomes were analysed.

Results:
The mean follow-up period was 16 months. Mean number of UTIs during observation was 5 (2–6). Infections with multi-drug resistant strains were observed in all patients before commencing fosfomycin prophylaxis, on average 21 days after urological procedure. Due to recurrent UTIs with highly resistant or reduced susceptibility strains, despite standard prophylaxis, we introduced fosfomycin in 50–70 mg/kg dose once a day for 4–9 months what reduced frequency of infections (3.6 vs. 1.0, p = 0.01), infections with decreased susceptibility strains (3.6 vs. 0.0, p = 0.00006) and need for hospitalisations (3.6 vs. 0.2, p = 0.003). Fosfomycin was introduced after 2–5 UTIs, at the mean age of 7 months, after mean of 4 months of ineffective standard prophylaxis. We didn’t record any significant adverse effects of the treatment or bacterial resistance development.

Conclusions:
In children with urinary tract malformations, and in particular with a history of urological interventions, in the case of recurrent UTIs with strains of reduced susceptibility to antibiotics, several months of non-standard prophylactic treatment with fosfomycin may be considered.
REFERENCES (28)
1.
Hoberman A, Wald ER, Hickey RW, et al. Oral versus initial intravenous therapy for urinary tract infections in young febrile children. Pediatrics 1999; 104: 79-86.
 
2.
Conway PH, Cnaan A, Zaoutis T, et al. Recurrent urinary tract infections in children: risk factors and association with prophylactic antimicrobials. JAMA 2007; 298: 179-186.
 
3.
Peters CA, Skoog SJ, Arant BS Jr., et al. Summary of the AUA guideline on management of primary vesicoureteral reflux in children. J Urol 2010; 184: 1134-1144.
 
4.
Montini G, Rigon L, Zucchetta P, et al. IRIS Group. Prophylaxis after first febrile urinary tract infection in children? A multicenter, randomized, controlled, noninferiority trial. Pediatrics 2008; 122: 1064-1071.
 
5.
Dai B, Liu Y, Jia J, et al. Long-term antibiotics for the prevention of recurrent urinary tract infection in children: a systematic review and meta-analysis. Arch Dis Child 2010; 95: 499-508.
 
6.
Morello W, La Scola C, Alberici I, et al. Acute pyelonephritis in children. Pediatr Nephrol 2016; 31: 1253-1265.
 
7.
Salo J, Ikaheimo R, Tapiainen T, et al. Childhood urinary tract infections as a cause of chronic kidney disease. Pediatrics 2011; 128: 840-847.
 
8.
American Academy of Pediatrics, Subcommittee on Urinary Tract Infection, Steering Committee on Quality Improvement and Management; Roberts KB. Urinary tract infection: clinical practice guideline for diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. Pediatrics 2011; 128: 595-610.
 
9.
Shaikh N, Ewing AL, Bhatnagar S, et al. Risk of renal scarring in children with a first urinary tract infection: a systematic review. Pediatrics 2010; 126: 1084-1091.
 
10.
RIVUR Trial Investigators; Hoberman A, Greenfield SP, Mattoo TK, et al. Antimicrobial prophylaxis for children with vesicoureteral reflux. N Engl J Med 2014; 370: 2367-2376.
 
11.
Brandstrom S, Esbjorner E, Herthelius M, et al. The Swedish reflux trial in children: III. Urinary tract infection pattern. J Urol 2010; 184: 286-291.
 
12.
Falagas ME, Vouloumanou EK, Samonis G, et al. Fosfomycin. Clin Microbiol Rev 2016; 29: 321-347.
 
13.
Grabein B, Graniger W, Rodriguez Bano J, et al. Intavenous fosfomycin – back to the future. Systematic rewiev and meta-analysis of the clinical literature. Clin Microbiol Infect 2017; 23: 363-372.
 
14.
Baquero F, Hortelano JG, Navarro M, et al. Anibiotherapy of Serratia mercesens septocemia in children. Chemotherapy 1977; 23 Suppl. 1: 416-422.
 
15.
Iarikov D, Wassel R, Farley J, et al. Adverse events associated with fosfomycin use: review of the literature and analyses of the FDA adverse event reporting system database. Infect Dis Ther 2015; 4: 433-458.
 
16.
Corti N, Sennhauser FH, Stauffer UG, et al. Fosfomycin for the initial treatment of acute haematogenous osteomyelitis. Arch Dis Child 2003; 88: 512-516.
 
17.
Traunmuller F, Popvic M, Konz K-H, et al. A reappraisal of current dosing strategies for intravenous fosfomycin in children and neonates. Clin Pharmacokinet 2011; 50: 493-503.
 
18.
Summary of Product Characteristics: https://rejestrymedyczne.ezdro....
 
19.
Kane Z, Gastine S, Obiero C, et al. IV and oral fosfomycin pharmacokinetics in neonates with suspected clinical sepsis. Randomized controlled trial. J Antimicrob Chemother 2021; 76: 1855-1864.
 
20.
Polat M, Ozkaya-Parlakay A, Tapısız A, et al. Oral fosfomycin for treating lower urinary tract infections due to multidrug-resistant Escherichia coli in female adolescents. J Chemother 2022; 34: 97-102.
 
21.
Rodríguez-Lozano J, de Malet A, Cano ME, et al. Antimicrobial susceptibility of microorganisms that cause urinary tract infections in pediatric patients. Enferm Infecc Microbiol Clin 2018; 36: 417-422.
 
22.
European Medicines Agency. Fosfomycin-containing medicinal products. https://www.ema.europa.eu/en/m....
 
23.
Qiao L, Chen S, Lin Y, et al. Evaluation of perioperative prophylaxis with fosfomycin tromethamine in ureteroscopic stone removal: an investigator-driven prospective, multicenter, randomized, controlled study. Randomized controlled trial. Int Urol Nephrol 2018; 50: 427-432.
 
24.
Costantini E, Zucchi A, Salvini E, et al. Prulifloxacin vs fosfomycin for prophylaxis in female patients with recurrent UTIs: a non-inferiority trial. Randomized controlled trial. Int Urogynecol J 2014; 25: 1173-1178.
 
25.
Rudenko N, Dorofeyev A. Prevention of recurrent lower urinary tract infections by long-term administration of fosfomycin trometamol. Double blind, randomized, parallel group, placebo-controlled study. Clinical Trial Arzneimittelforschung 2005; 55: 420-427.
 
26.
Kuiper SG, Dijkmans AC, Wilms EB, et al. Pharmacokinetics of fosfomycin in patients with prophylactic treatment for recurrent Escherichia coli urinary tract infection. J Antimicrob Chemother 2020; 75: 3278-3285.
 
27.
Falagas ME, Kastoris AC, Kapaskelis AM, et al. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum β- lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 2010; 10: 43-50.
 
28.
Ríos E, López Diaz M, Culebras E, et al. Resistance to fosfomycin is increasing and is significantly associated with extended-spectrum β-lactamase-production in urinary isolates of Escherichia coli. Med Microbiol Immunol 2022; 211: 269-272.
 
Journals System - logo
Scroll to top